Compare INGN & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INGN | CHRS |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.1M | 209.8M |
| IPO Year | 2013 | 2014 |
| Metric | INGN | CHRS |
|---|---|---|
| Price | $6.31 | $1.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $11.25 | $5.51 |
| AVG Volume (30 Days) | 195.1K | ★ 760.7K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 43.42 | ★ 472.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $348,668,000.00 | N/A |
| Revenue This Year | $8.03 | $73.08 |
| Revenue Next Year | $7.76 | $30.94 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.86 | N/A |
| 52 Week Low | $5.34 | $0.81 |
| 52 Week High | $9.13 | $2.62 |
| Indicator | INGN | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 48.07 | 49.00 |
| Support Level | $6.00 | $1.38 |
| Resistance Level | $6.73 | $1.76 |
| Average True Range (ATR) | 0.24 | 0.07 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 41.79 | 31.82 |
Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.